6L9.F · ViewRay, Inc

-

Please sign in to comment on 6L9.F

1 Comment

Admin

3 years, 7 months ago

ViewRay, Inc is currently in a long term uptrend where the price is trading 46.8% above its 200 day moving average.

From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.6.

ViewRay, Inc's total revenue rose by 12.1% to $18M since the same quarter in the previous year.

Its net income has increased by 25.9% to $-26M since the same quarter in the previous year.

Finally, its free cash flow fell by 146.5% to $-8M since the same quarter in the previous year.

Based on the above factors, ViewRay, Inc gets an overall score of 4/5.

CurrencyCode	EUR
Exchange	F
Industry	Medical Devices
Sector	Healthcare
ISIN	US92672L1070

Target Price	8
Dividend Yield	0.0%
Beta	1.01
PE Ratio	None
Market Cap	250M

ABOUT

ViewRay, Inc

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.

6L9.F · ViewRay, Inc

-

ViewRay, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest ViewRay, Inc using a moving average strategy